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The impact of control and elimination programmes by mass drug administration (MDA) targeting onchocerciasis
and lymphatic filariasis (LF) in sub-Saharan Africa over the last two decades has resulted in significantly reduced
prevalence and intensity of infection, with some areas interrupting transmission. However, given that these
infections are often co-endemic and the drugs (either ivermectin alone or combined with albendazole) also impact
on soil transmitted helminths (STH), the importance of this, in terms of reaching the global goals has not been
assessed. The additional problem posed by Loa loa, where ivermectin cannot be safely administered due to the risk
of serious adverse events compounds this situation and has left populations drug naïve and an alternative strategy
to eliminate LF is yet to be initiated at scale. Here, we present a series of operational research questions, which
must be addressed if the effectiveness of integrated control of filarial and helminth infections is to be understood
for the endgame. This is particularly important in the diverse and dynamic epidemiological landscape, which has
emerged as a result of the long-term large-scale mass drug administration (or not). There is a need for a more
holistic approach to address these questions. Different programmes should examine this increased complexity,
given that MDA has multiple impacts, drugs are given over different periods, and programmes have different
individual targets.
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Mass drug administration, Albendazole, Ivermectin, Bed netsBackground to large-scale programmes
The filarial infections of humans in Africa demonstrate a
wide spectrum of pathology and epidemiology as well as
a diversity of vectors, ecology and distribution [1]. Im-
posed on this already complex pattern have been large-
scale intervention programmes, ongoing for 40 years,
initially for onchocerciasis, and since 2000 for lymphatic
filariasis (LF) [2-7]. These programmes have reduced the
public health importance of onchocerciasis and LF in
many parts of Africa including interrupting transmission
in some areas [4,8-12] through mass drug administration
(MDA) as well as vector control, or a combination of
both approaches [13-16].* Correspondence: David.Molyneux@lstmed.ac.uk
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unless otherwise stated.The Onchocerciasis Control Programme in West
Africa (OCP) launched in 1974 [17] was initially consid-
ered to be addressing a relatively homogenous and well
defined epidemiological situation. However, gradually
during the period of its operations, research studies on
blackfly (Simulium ssp.) populations demonstrated sig-
nificant ecological and epidemiological complexity
[18-20]. The drug Mectizan® (ivermectin-MSD) donated
by Merck & Co Inc., was added as an annual treatment
to the OCP interventions in 1988. This produced, where
used, a rapid beneficial impact on morbidity and the
progression of ocular lesions, thus preventing many
cases of irreversible blindness as well as reducing the re-
quired duration of vector control by some two years [2].
Donated ivermectin was the cornerstone intervention
used by the African Programme of Onchocerciasis Con-
trol (APOC) established in 1995 [21] (and by the On-
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able delivery platform for ivermectin by adopting a pol-
icy of community directed delivery of ivermectin (CDTi)
[25]. The objective was to facilitate the long term sus-
tainable control of the public health problem due to on-
chocerciasis whilst reducing ocular and skin disease
morbidity [5]; however, elimination was not considered
to be a feasible goal at the time [26].
Diversity of settings, epidemiology and
interventions
The diversity of the settings in which the OCP was re-
quired to work in and deliver interventions [20], led to the
concept of control epidemiology, which required a varied
response to the endgame of OCP depending on the eco-
geography of the vector and parasite (Simulium spp.
/Onchocerca volvulus) complexes throughout the 11 coun-
tries of the OCP in West Africa. This was due to the
different vectorial capacity of local Simulium species/cyto-
forms, defined by annual transmission potentials, initial
prevalence levels and intensities as measured by commu-
nity microfilarial loads and the varied pathology of forest
and savannah forms of O. volvulus [2]. Over the last
decade MDA programmes for onchocerciasis, LF and soil-
transmitted helminths (STHs) have expanded in sympat-
ric/co-endemic filarial infection settings throughout Africa
[7,27,28]. This increased diversity of the epidemiology
(ecology, zoogeography, vector characteristics, infection
prevalence and intensity) needs to be addressed in a com-
prehensive way in the context of integrated neglected
tropical disease (NTD) control/elimination.
Particular regard needs to be paid to coordinated map-
ping, and the dynamics created by ongoing interventions
using drugs, which have an impact on filarial and hel-
minth infections. This is important as individual disease
specific programmes have expanded or are reaching end-
points, whilst there is the drive to integrate MDA using
the preventive chemotherapy (PC) strategy for other in-
fections such as trachoma and schistosomiasis [26]. For
example, in Niger and some areas of Uganda where all
indications are that onchocerciasis has been eliminated,
treatment is ongoing with ivermectin and albendazole to
complete the requirements of the LF programme. The
reverse is true in the few countries where LF pro-
grammes have achieved the endpoints and treatment
campaigns have stopped. Post-treatment surveillance
(PST) will be a critical operation for national health sys-
tems to ensure that the public health gains, achieved at
great cost over many years are not lost to undetected
recrudescence.
The original epidemiological patterns of individual
disease prevalence and intensity have thus become more
diverse and complex as multiple control/elimination
strategies, deploying a variety of drug combinations,with differential efficacies have been initiated and ex-
panded over time. Levels of population coverage vary, as
do target populations, and in the case of LF, the impact
on transmission will vary if the programme overlaps
with a previously treated onchocerciasis area or bed
net/ long lasting insecticidal nets (LLINs) distribution
for malaria control where over many areas the diseases
are co-endemic [29]. In sub-Saharan Africa, initially
control, and now the elimination of onchocerciasis and
of LF has been targeted in parallel with the expansion of
integrated MDA using the PC strategy, which also targets
STH, schistosomiasis and trachoma [28]. MDA delivered
through communities or via school based programmes
targeting school age children are the core modes of deliv-
ery for STH and schistosomiasis. The drugs used for these
programmes in sub-Saharan Africa are ivermectin, alben-
dazole, mebendazole, praziquantel and azithromycin - all
donated by pharmaceutical companies and are on the
WHO Essential Medicine drugs list [3,30]. Figure 1 high-
lights the complexity of cross-cutting treatment and inter-
ventions for helminthiases, which need to consider multiple
epidemiological scenarios and include malaria vector con-
trol as either an alternative or additional strategy in certain
co-endemic situations [13,29].
The wider impacts of some of these drugs, the diver-
sity of the disease ecology, extent of co-endemicity, the
duration of targeted treatments required to eliminate
some infections such as onchocerciasis and LF, as well
as the complexity of the inter-disease epidemiology cre-
ates significant conceptual problems. To date the NTD
community has tended to seek answers to unique ques-
tions, which relate to one or two diseases. This is best
exemplified in the case of LF, where the impact of previ-
ous distributions of ivermectin, albendazole and bed
nets/LLINs need to be investigated [13,31,32]. There has
been limited recognition of the extent of the distribution
of bed nets/LLINs over the last decade and the potential
impact they may have had, in the absence of MDA in
some LF endemic areas [13-16,29]. A further consideration
of the bed nets/LLINs on LF (as in malaria) will be the pat-
terns of insecticide resistance, which will in the future add
to the complexity of monitoring and evaluating LF pro-
grammes [33,34]. This has not previously been considered.
There is also recognition that there is a need for an ef-
fective macrofilaricide to kill or permanently sterilise
adult worms. The evidence that doxycycline is effective
as it targets Wolbachia endosymbionts in both Oncho-
cerca and Wuchereria has been known for over a decade
[35]. However, there is now an opportunity to oper-
ationalise this approach albeit on a limited scale under
medical supervision, whilst research to reduce the dur-
ation of antibiotic treatments and find additional suit-
able antibiotics continues. Studies in Cameroon have
shown that there is high compliance by communities to
DEC              Ivermectin              Albendazole         Bed nets/LLINs
LF endemic
LF /Oncho co-endemic
LF / Loa loa co-endemic 
MalariaSTHOncho
Type of treatment or intervention for each disease or co-endemicity
Figure 1 Cross-cutting treatments and intervention for helminthiases (filarial and soil–transmitted) and malaria. For STH moderate
endemic areas (prevalence >20%) once yearly albendazole treatment is given, and in high endemic areas (prevalence >50%) twice yearly
albendazole treatment is given. For LF/L loa co-endemic areas twice yearly albendazole treatment is given together with bed nets/LLINs.
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This should be exploited in areas/hotspots where there
is suggested reduced efficacy of ivermectin or albenda-
zole for both diseases, or predicted rates of decline of
prevalence have not been in accord with those expected.
There is also a need to introduce twice a year ivermec-
tin, as has been the approach in the OEPA programme,
in certain sub-Saharan Africa settings where this twice
yearly regime may be better able to reduce the duration
of annual treatments to achieve elimination of transmis-
sion of O. volvulus [22-24]. We summarise below the
key operational research questions we consider must be
addressed over the coming years in LF/onchocerciasis
co-endemic areas.
The key questions that can be posed to address the
multidimensional complexity of the current problems of
MDA in LF/ onchocerciasis co-endemic areas (not L. loa
endemic).
Impact of MDAs on non-targeted infections
➢Some 20 project areas of APOC have reached a level
where transmission (as measured by entomological
studies and mf prevalence) has been reduced to a level
compatible with achieving elimination of onchocerciasis;
many of these areas are likely to have had endemicWuchereria bancrofti; what has been the impact of
ivermectin given annually for 15 years on endemic LF?
➢What has been the impact of ivermectin alone and
with albendazole MDA for onchocerciasis and LF on
STH and scabies [12]?; how has this impacted on
mapping STH and on the prioritisation of interventions?
Onchocerciasis elimination and LF: the new questions
➢What is the geographic extent of the onchocerciasis
low transmission zones and the population to be
covered (hypoendemic areas previously untreated with
ivermectin), which now need to be treated if
onchocerciasis elimination is to be achieved, and how
do they overlap with LF?
➢Have the hypoendemic onchocerciasis areas already
been subjected to MDA for LF (where, when and for
how long) and if so, what impact has that intervention
had on onchocerciasis prevalence and intensity; has it
been eliminated or prevalence reduced?
New strategies to address elimination: when, where,
who and how
➢What is the feasibility of introducing twice yearly
treatments of ivermectin to reduce the duration of
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(cf OEPA); what will be the impact on questions posed
above; where should this approach be tested in Africa?
What impact would this strategy have on LF?
➢Under what circumstances should doxycycline (or
other anti Wolbachia antibiotics) be introduced as a
macrofilaricidal strategy; what is needed to initiate such
approaches, where and at what scale?
Impact of bed nets/LLINs
➢What has been the impact of bed nets/LLINs on their
own or concurrently with ivermectin MDA on the
distribution and prevalence of LF, and are LF specific
interventions still needed [13-16,29]?
➢What is the extent of the areas covered by bed nets
/LLINs where LF had low endemicity/prevalence levels
(implementation units prevalence circa 1-5%) as
recorded during initial mapping studies [37-39], and
do these areas now need MDA for LF given the
threshold level of 1% as the recommendation for an
intervention for 5–7 years. If not, what is required to
confirm elimination?
➢How long will LLINs remain efficacious as
insecticide resistance to pyrethroids increases; what
impact will a reduced LLIN efficacy have on the LF
endgame [33,34]?
STH interventions, strategies and interactions
➢Do the STH school based delivery strategies require
modification given the impact of ivermectin and
albendazole on STH where the drugs have been used for
onchocerciasis and filariasis control?
➢To what extent, if any, has the treatment of adults
within the onchocerciasis and LF programmes for
extended periods impacted on transmission of STH; is
this a question which needs to be addressed given the
emphasis on the need to treat adults as well as
children if the impact of STH treatments are to be
maximised [40-42]?
➢What impact does STH deworming using albendazole
and mebendazole of school age children have on LF
either pre or post MDA interventions [41,42]?
Loa loa - the monster in the room
During the early phase of the CDTi programme in
Cameroon, severe adverse events (SAEs) were reported
[43] from areas co-endemic with the filarial parasite Loa
loa. Some individuals who had high densities of L. loa
microfilaria (≥30,000/ml) and who received ivermectin
developed encephalopathic reactions following treatment
[44]. Following the reports of SAEs in Cameroon, safety
concerns prevented the wider expansion of CDTiprogrammes to eliminate onchocerciasis and LF in areas
co-endemic with L. loa where there is the possibility of
treating over 90% of the population who are not in-
fected. The situation remains a major challenge and has
prevented the initiation of LF programmes [3,7] using
ivermectin with albendazole in MDA. Treatment with
ivermectin is continuing in areas of meso and hyperen-
demic onchocerciasis where it is considered the risks of
an SAE is justified due to the long-term effects of on-
chocerciasis in the population. In these areas, strict
guidelines were put in place for the early identification
and management of SAE cases, reducing the mortality
and morbidity considerably.
The problems presented by the risk of SAEs have re-
quired the search for alternative elimination strategies for
deployment in LF/L. loa co-endemic areas. This has re-
sulted in the recommendation that twice yearly albenda-
zole be implemented together with the expanded use of
bed nets/LLINs, which are now widely used for malaria
control [3,45]. To address the problems of SAEs it was ne-
cessary to identify areas of highest risk of loiasis in oncho-
cerciasis endemic areas; a field-applicable non-invasive
rapid assessment technique was developed (RAPLOA) to
address this. A survey was administered on the ability of
villagers to identify the presence of the L. loa adult in the
eye. A questionnaire which asked about the history of eye
worm using a restricted definition was developed, and re-
sults were based on the proportion of individuals who had
a history of eye worms confirmed by a photograph or a
Calabar swelling that lasted 1–7 days [46,47]. The studies
indicated that the rapid assessment method produced a
strong correlation between parasitological indices and
those obtained by questionnaire.
Recent studies on SAEs in Bas Congo, DRC [48], have
shown that the events are associated with areas considered
to be at lower risk with a RAPLOA prevalence of between
20-40%, but were found to be 10–16 times higher than
elsewhere. This implies that the RAPLOA estimated
prevalence is not necessarily the primary indicator of SAE
risk, but rather the intensity of infection in individuals when
they have high parasitaemias of L. loa (≥30,000 mf/ml) [49].
This is a feature not predicated in any overall preva-
lence data [50] - but something that needs to be exam-
ined on a finer spatial scale taking into account human
population densities, age-sex compositions, movement
and migration, and local environmental factors such as
vegetation and forest cover. These are important to
Chrysops spp. vectors and their potential to breed, bite,
transmit and maintain infection in the community [51].
Hence, given the wide geographical range of the
RAPLOA 20-40% intermediate prevalence zones across
Central and West Africa (Figure 2), the risk of Loa en-
cephalopathies are likely to be more extensive than pre-
viously estimated. This is important in the context of
20% to 40% 
> 40%
Loiasis - prevalence 
Figure 2 Loiasis intermediate and high risk subnational areas. Risk coding based on loiasis map by Zouré et al. [47] and created using
country sub-national boundaries in ArcGIS (ESRI, Redlands, CA).
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sion areas and where onchocerciasis elimination requires
MDA over perhaps at least a 10 year period and where
LF prevalence is also above 1% and where MDA should
be initiated. Thus, the recommended strategy of twice
yearly albendazole in combination with bed nets/LLINs
for LF programmes [45] will extend through areas of L.
loa endemicity irrespective of RAPLOA risk mapping as
the sensitivity of the 20-40% intermediate zone is based
purely on a questionnaire [46,52]. Within all these co-
endemic zones the impact on LF transmission over re-
cent years needs to be better estimated based on recent
bed nets/LLIN coverage, usage and efficacy [29,41]. This
is a major area currently lacking attention within manyA. Loiasis > 20% B. Onchocerciasis>20%(CD
D. Loiasis overlapping CDTi areas E. Loiasis overlapping non-
+
Figure 3 Maps of loiasis intermediate and high risk areas geographic
indicates loiasis intermediate prevalence areas of 20-40%. Red shading indi
onchocerciasis > 20% and areas targeted with ivermectin, also known as CD
C. Loiasis and CDTi area overlap D. Loiasis overlapping CDTi areas E. LoiasisLF programmes. Similarly, there is little information of
the extent and impact of CDTi activities to date where
there may be or have been W. bancrofti endemicity.
Here we use DRC as a case study to highlight the com-
plexities and challenges for the new LF programme scaling
up MDA across large hard-to reach- L. loa co-endemic
areas [47]. Figure 3 shows the wide loiasis and CDTi over-
lapping distributions across the country (Figure 3A-C), and
highlights that many intermediate/high risk loiasis areas
have already received multiple rounds of ivermectin
(Figure 3D), and that there are far fewer areas than ex-
pected that are totally drug naïve and non-CDTi areas
(Figure 3E). However, what is important to note is that in
the drug naïve areas in the east of the country, there is aOnchocerciasis - prevalence(CDTiareas) 




Tiareas) C. Loiasis and CDTi area overlap
CDTi areas 
ally overlapping with CDTi and non-CDTi areas. Orange shading
cates loiasis high prevalence areas of > 40%. Blue shading indicates
Ti areas. A. Loiasis >20% B. Onchocerciasis >20% (CDTi areas)
overlapping non-CDTi areas.
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and infrastructure barriers to reaching this vulnerable
population [53]. We summarise below the key questions
we consider must be addressed over the coming years by
LF programmes in LF/onchocerciasis/L. loa co-endemic
areas.
The key programmatic and research questions which can
be posed to address the multidimensional complexity of the
current problems of MDA in LF/ onchocerciasis/ L. loa
co-endemic areas
Compliance/adherence, coverage and cooperation
➢In LF/L. loa co-endemic areas that overlap CDTi
areas, which have already received multiple rounds of
ivermectin, what does adding albendazole do for com-
pliance /adherence?
➢Have coverage levels of ivermectin through the CDTi
platform been high enough to avert SAEs with the rigor
of a new LF programme, which may reach populations
previously untreated or sub-optimally treated?
➢How does the LF programme scale up the alternative
strategy of twice yearly albendazole and bed nets/LLINs in
LF/L. loa co-endemic /non-CDTi areas, especially in remote
inaccessible areas with limited bed nets /LLIN coverage and
where no MDA has yet been implemented [53]?
➢How does the LF programme engage with the malaria
control programme to coordinate, distribute and
maintain adequate coverage of LLINs where they are
needed most; who will monitor insecticide resistance?
[54]; do potential SAE areas overlap malaria endemic
areas?
Consequential impact of alternative strategies
➢What will be the impact of the alternative strategy
including twice yearly albendazole for L. loa endemic areas
on STH distribution? How does the LF programme engage
with new STH programmes scaling up in country, share
resources and measure impact across the multiple diseases?
➢Will the alternative strategy of twice yearly
albendazole for L. loa have the same impact across a
diverse range of ecological and epidemiological settings;
how will it be measured and monitored?
➢What will be the impact of the alternative strategy,
including twice yearly albendazole be on O. volvulus,
especially low transmission/hypo-endemic areas, in the
absence of ivermectin?
Review and conclusions
The NTD community must recognise that implementation
of the current strategy through a single disease specific
focus, whilst expanding through integrated implementation
strategies, must adapt its approach to the multidimensional
challenges now presented. This is indicated by the widerimplications of the impact of the drugs already distributed,
the long term impact of ivermectin and albendazole on
STH where some 200 million treatments are given annually
in Africa for onchocerciasis and LF [7] and the impact of
bed nets/LLINs on W. bancrofti and its transmission
[13-16,29]. For STH, whilst the current focus is on the
treatment of school age children, the need to treat pre-
school aged children and those pupils not attending school
needs significant consideration [55]-for example are they
receiving treatment through onchocerciasis and LF pro-
grammes if under 90 cms height. These important cohorts
of the population will require treatment and systematic
surveillance.
Recently, the importance of treating adults and the
need for water and sanitation (WASH) programmes has
been emphasised if “elimination” is to be achieved [56],
but the impact of onchocerciasis and LF interventions
which have been distributed for almost two decades for
onchocerciasis and a decade for LF with over 2 billion
treatments given cumulatively in Africa must be factored
into the evaluation, and mapping models to reflect im-
pact on one hand, and accuracy and sensitivity of any
mapping to determine future interventions, on the
other.
We believe the questions we pose are operationally
critically important in the context of the established
Roadmap targets [28]; these issues affect strategy, policy,
operational and implementation issues and are particu-
larly critical in the context of mapping, planning, moni-
toring and evaluation, surveillance and elimination.
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